Lipocine Inc. (NASDAQ: LPCN) is 284.52% higher on its value in year-to-date trading and has touched a low of $0.30 and a high of $3.45 in the current 52-week trading range. The LPCN stock was last observed hovering at around $1.65 in the last trading session, with the day’s loss setting it -0.17% off its average median price target of $3.00 for the next 12 months. It is also 50.67% off the consensus price target high of $3.00 offered by 2 analysts, but current levels are 50.67% higher than the price target low of $3.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $1.48, the stock is -22.99% and -5.27% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.18 million and changing -10.30% at the moment leaves the stock 86.20% off its SMA200. LPCN registered -49.66% loss for a year compared to 6-month gain of 171.66%. The firm has a 50-day simple moving average (SMA 50) of $1.7079 and a 200-day simple moving average (SMA200) of $0.9615.
The stock witnessed a -3.90% loss in the last 1 month and extending the period to 3 months gives it a 66.33%, and is -13.95% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 16.39% over the week and 11.84% over the month.
Lipocine Inc. (LPCN) has around 12 employees, a market worth around $97.24M and $0.20M in sales. Distance from 52-week low is 391.69% and -57.10% from its 52-week high. The company has generated returns on investments over the last 12 months (-96.30%).
Lipocine Inc. (LPCN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Lipocine Inc. (LPCN) is a “Overweight”. 2 analysts offering their recommendations for the stock have an average rating of 2.50, where 1 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Lipocine Inc. is expected to release its quarterly report on 11/04/2020 and quarterly earnings per share for the current quarter are estimated at -$0.06.The EPS is expected to grow by 8.00% this year.
Lipocine Inc. (LPCN) Top Institutional Holders
34 institutions hold shares in Lipocine Inc. (LPCN), with 2.41M shares held by insiders accounting for 3.68% while institutional investors hold 18.44% of the company’s shares. The shares outstanding are 65.69M, and float is at 63.81M with Short Float at 4.04%. Institutions hold 17.76% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 1.1 million shares valued at $1.39 million. The investor’s holdings represent 1.68% of the LPCN Shares outstanding. As of Jun 29, 2020, the second largest holder is Ameriprise Financial, Inc. with 0.79 million shares valued at $0.99 million to account for 1.20% of the shares outstanding. The other top investors are Blackrock Inc. which holds 0.72 million shares representing 1.10% and valued at over $0.91 million, while Renaissance Technologies, LLC holds 0.48% of the shares totaling 0.32 million with a market value of $0.4 million.
Lipocine Inc. (LPCN) Insider Activity
A total of 1 insider transactions have happened at Lipocine Inc. (LPCN) in the last six months, with sales accounting for 0 and purchases happening 1 times. The most recent transaction is an insider purchase by Higuchi John W., the company’s Director. SEC filings show that Higuchi John W. bought 220,000 shares of the company’s common stock on Mar 17 at a price of $0.32 per share for a total of $69542.0. Following the purchase, the insider now owns 0.7 million shares.
Lipocine Inc. disclosed in a document filed with the SEC on Dec 31 that Patel Mahesh V. (CEO and President) bought a total of 40,000 shares of the company’s common stock. The trade occurred on Dec 31 and was made at $0.38 per share for $15340.0. Following the transaction, the insider now directly holds 0.97 million shares of the LPCN stock.
Still, SEC filings show that on Dec 10, Patel Mahesh V. (President and CEO) acquired 25,000 shares at an average price of $0.40 for $9975.0. The insider now directly holds 933,612 shares of Lipocine Inc. (LPCN).
Lipocine Inc. (LPCN): Who are the competitors?
The company’s main competitors (and peers) include SIGA Technologies Inc. (SIGA) that is trading 38.45% up over the past 12 months. Seattle Genetics Inc. (SGEN) is 117.98% up on the 1-year trading charts. Short interest in the company’s stock has risen 69.16% from the last report on Jul 14, 2020 to stand at a total of 0.8 million short shares sold with a short interest ratio of 0.63.